Efficacy of sodium glucose cotransporter 2 inhibitors as an adjunct treatment for patients with diabetes type 2

2019 ◽  
Vol 152 (11) ◽  
pp. 438-441
Author(s):  
Pedro Pujante ◽  
Jessica Ares ◽  
Carmen Maciá ◽  
Raúl Rodriguez Escobedo ◽  
Edelmiro Menéndez ◽  
...  
Keyword(s):  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Adjunct Treatment ◽  
Sodium Glucose Cotransporter ◽  
Patients With Diabetes

Efficacy of sodium glucose cotransporter 2 inhibitors as an adjunct treatment for patients with diabetes type 2

2019 ◽  
Vol 152 (11) ◽  
pp. 438-441
Author(s):  
Pedro Pujante ◽  
Jessica Ares ◽  
Carmen Maciá ◽  
Raúl Rodriguez Escobedo ◽  
Edelmiro Menéndez ◽  
...  
Keyword(s):  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Adjunct Treatment ◽  
Sodium Glucose Cotransporter ◽  
Patients With Diabetes

Risk Factors Associated With Hyperuricemia in Patients with Diabetes Type 2: About 190 Cases

2020 ◽  
Vol 2 (1) ◽  
pp. 12-16
Author(s):  
Fennoun H ◽  
Haraj NE ◽  
El Aziz S ◽  
Bensbaa S ◽  
Chadli A
Keyword(s):  
Type 2 Diabetes ◽  
Heart Disease ◽  
Glycemic Control ◽  
Ischemic Heart Disease ◽  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Ischemic Heart ◽  
Factors Associated ◽  
Patients With Diabetes

Introduction: Hyperuricemia is common Type 2 diabetes at very high cardiovascular risk. Objective: Evaluate the relationship between hyperuricemia and diabetes type 2, and determine its predictive factors in this population. Patients and Methods: Retrospective study cross including 190 patients with diabetes type 2 hospitalized Service of Endocrinology of CHU Ibn Rushd Casablanca from January 2015 to December 2017. Hyperuricemia was defined as a serum uric acid concentration> 70 mg/L (men) and> 60 mg/L (women). The variables studied were the anthropometric measurements), cardiovascular factors (tobacco, hypertension, dyslipidemia), and degenerative complications (retinopathy, neuropathy, kidney failure, ischemic heart disease). The analyzes were performed by SPSS software. Results: Hyperuricemia was found in 26.5% of patients with a female predominance (76%), an average age of 55.9 years, and an average age of 12.4ans diabetes. The glycemic control was found in 84.6% of cases with mean glycated hemoglobin 8.6%. Factors associated al hyperuricemia were the blood pressure in 86% (p <0.05), dyslipidemia in 76.3% of cases (p <0.001) with hypertriglyceridemia in 48.3% of cases (p <0.02), and a hypoHDLémie 28% (p <0.001). The age, obesity, smoking, and glycemic control were associated significantly n al hyperuricemia. The research of degenerative complications of hyperuricemia has objectified renal impairment (GFR between 15 and 60ml / min) chez47% (p <0.001), it was kind of moderate in 35.8% (p <0.01) and severe in 5.1% (p <0.02), ischemic heart disease was found in 34% of cases (p <0.01). Conclusion: In our study, hyperuricemia in type 2 diabetes is common in female patients, especially with hypertension, dyslipidemia, and renal failure. Other factors such as age, obesity, smoking is not associated with hyperuricemia in type 2 diabetics.

scholarly journals The Effects of Combined Insulin and Metformin Therapy in Obese Patients with Diabetes Mellits Type 2 in the Early Stage of the Disease

2006 ◽  
Vol 6 (2) ◽  
pp. 54-58
Author(s):  
Belma Aščić - Buturović
Keyword(s):  
Insulin Therapy ◽  
Pancreatic Beta Cells ◽  
Early Stage ◽  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Target Cells ◽  
Obese Patients ◽  
Patients With Diabetes ◽  
Insulin Activity

Combination of insulin and metformin has been shown to improve glycaemic control in clinical trials, particularly in obese patients with diabetes type 2. Insulin therapy can improve function of pancreatic beta cells and periphery insulin activity in target cells in order to enhance glycaemic homeostasis (1, 2, 3). In our study we included obese patients with diabetes type 2 in the early stage of the disease. The study is partially retrospective and partially prospective. The study encompassed 40 patients split in two groups. The first group of 20 patients received insulin therapy combined with metformin, while the patients of the second group were treated with oral antidiabetic drugs, sulfonylureas and metformin. Three months later, the group treated with insulin and metformin showed improvement in the monitored parameters, namely significant reduction in HbA1c (p = 0.003), MFBG (p = 0.0009), PPG (p = 0.028). Insulin therapy administered together with metformin, in obese patients with diabetes type 2, in the early stage of the disease, resulted in well regulated fasting blood glycaemia, as well as post challenge glycaemia and HbA1c.

DETECTION OF PULMONARY HYPERTENSION IN COPD PATIENTS WITH DIABETES TYPE 2 (DM2)

CHEST Journal ◽  
2006 ◽  
Vol 130 (4) ◽  
pp. 172S
Author(s):  
Alexander E. Makarevich ◽  
Valentina E. Valevich ◽  
Alexander J. Pochtavcev
Keyword(s):  
Pulmonary Hypertension ◽  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Copd Patients ◽  
Patients With Diabetes

Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment

2007 ◽  
Vol 46 (6) ◽  
pp. 1111-1118 ◽  
Author(s):  
Peter Rosenberg ◽  
Hanna Urwitz ◽  
Anders Johannesson ◽  
Anne-Marie Ros ◽  
Johan Lindholm ◽  
...  
Keyword(s):  
High Risk ◽  
Liver Fibrosis ◽  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Patients With Diabetes ◽  
Methotrexate Treatment
Sign in / Sign up

Export Citation Format

Share Document